PhaseBio Pharmaceuticals, Inc. filed a motion in the US Bankruptcy Court seeking the extension of its exclusivity periods on February 17, 2023. As per the motion, the debtor seeks to extend its exclusivity periods for both, to file a plan and to solicit votes on a plan, by 90 days i.e., up to May 22, 2023, and July 20, 2023, respectively. The debtor's current exclusivity period and solicitation period would expire on February 21, 2023, and April 21, 2023, respectively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 49 | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHAS.Q Stock
- News PhaseBio Pharmaceuticals, Inc.
- First Motion for Exclusivity Period Extension Filed by PhaseBio Pharmaceuticals, Inc.